Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Antihyperlipidemic screening and plasma uric acid reducing potential ofHeliyon · 2019
   Article
2. HDL subfractions and very early CAD: novel findings from untreated patients in a Chinese cohort.Scientific reports · 2016
   Article
3. Large HDL Subfraction But Not HDL-C Is Closely Linked With Risk Factors, Coronary Severity and Outcomes in a Cohort of Nontreated Patients With Stable Coronary Artery Disease: A Prospective Observational Study.Medicine · 2016
   Observational
4. Exploring the factors that affect blood cholesterol and heart disease risk: is dietary cholesterol as bad for you as history leads us to believe?Advances in nutrition (Bethesda, Md.) · 2012
   Article

Corrections and comments

• Comment on
  Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease.2009

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as